OpenAI announced on Tuesday that it has acquired Orchestra Bio, a four‑year‑old AI biotech software startup. The companies did not disclose the financial terms of the deal. Orchestra had reportedly raised around $20 million as of 2025 from investors including Andreessen Horowitz, Atria, and 8VC.
What Orchestra does
Orchestra builds AI agents that assist biotechnology companies with operational aspects of drug discovery and development. Its tools cover tasks such as tracking finances and resolving scheduling issues for clinical trials.
Why OpenAI bought Orchestra
OpenAI said it will integrate Orchestra’s team and technology into Rosalind, its AI model for life sciences research, and into the related Rosalind Workbench tool. Rosalind and the Workbench are intended to help researchers plan experiments and analyze results. OpenAI has already named customers for Rosalind, including Moderna and Novo Nordisk.
Industry context
The acquisition reflects a broader pattern in which major AI labs — notably OpenAI and Anthropic — are developing increasingly specialized software for big industries like pharmaceuticals. Startups in the space often worry that the labs could launch overlapping features and become direct competitors; in this instance, Orchestra has been absorbed into OpenAI rather than remaining an independent rival.
Announcement details
OpenAI announced the acquisition on its website but did not provide additional financial details or a precise closing date beyond the statement.
